Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting.

Scarffe, Andrew D; Licskai, Christopher J; Ferrone, Madonna; Brand, Kevin; Thavorn, Kednapa; Coyle, Doug

Scarffe, Andrew D; Licskai, Christopher J; Ferrone, Madonna; Brand, Kevin; Thavorn, Kednapa; Coyle, Doug.

Scarffe AD; Telfer School of Management, University of Ottawa, 55 Laurier Avenue East, Ottawa, ON, K1N 6N5, Canada. ascar083@uottawa.ca.
Licskai CJ; London Health Sciences Centre, Western University, London, ON, Canada.
Ferrone M; Lawson Health Research Institute, London, ON, Canada.
Brand K; Asthma Research Group Windsor Essex County Inc., ON, Windsor, Canada.
Thavorn K; Asthma Research Group Windsor Essex County Inc., ON, Windsor, Canada.
Coyle D; Hotel-Dieu Grace Healthcare, Windsor, ON, Canada.

Cost Eff Resour Alloc ; 20(1): 39, 2022 Aug 12.

Article en En | MEDLINE | ID: mdl-35962399

Palabras clave

COPD; Chronic obstructive pulmonary disease; Cost-effectiveness; Cost-utility; Integrated disease management; Primary care

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Health_economic_evaluation / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google